
Schrödinger Inc. (NASDAQ:SDGR) announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate SGR-1505 in patients with relapsed or refractory B-cell lymphoma.
The Phase 1 clinical study will evaluate the safety, pharmacokinetics, pharmacodynamics of SGR-1505 in patients with relapsed or refractory B-cell lymphoma.